Kidney Disease, Chronic
69
11
16
29
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
11 trials with published results (16%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.8%
4 terminated out of 69 trials
87.9%
+1.4% vs benchmark
10%
7 trials in Phase 3/4
38%
11 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 29 completed trials
Clinical Trials (69)
Adia Med of Winter Park LLC Chronic Kidney Disease Research Study
Testosterone Treatment in Men With Chronic Kidney Disease
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Rutgers University Study of the Genetics of Kidney Disease
A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF)
Targeted Education ApproaCH to Improve Peritoneal Dialysis Outcomes Trial
Monitoring of the Sympathetic/Vagal Balance Through Multiparametric Analysis of Heart Rate Variability (HRV)
Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease
Physical Exercise and Biomolecular Analysis to Reduce Uremic Toxins in Chronic Kidney Disease: An Exploratory Study
Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus
KTRSensor Scotland Study: An Observational Study Into Predictors and Diagnosis of Kidney Transplant Rejection
Clinical Evaluation of the Nova Max Pro StatSensor Device
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
Ketoanalogue Supplementation for Muscle Protection in CKD 4 and 5 Patients With Moderately Low Protein Diet (KETO-PROT-ACTION)
A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
Mesenchymal Stem Cells for Chronic Kidney Diseases
An Observational Study of Patients With Chronic Kidney Disease
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
Patient-centered Precision Medicine Lab Result Communication for Older Adults